G.d. Searle & Company

Pharmacia Corporation

Ironwood Pharmaceuticals, Inc.

Microbia, Inc.

C. D. Searle & Co.

Barbara B Chen

Mark Andrew Russell

Thomas Dale Penning

Gunnar J Hanson

John S Baran

Michael John Clare

Alan Frank Gasiecki

Nizal S Chandrakumar

Helen Y Chen

Ish K Khanna

Julie M Miyashiro

Richard A Haack

Thomas Edward Rogers

James W Malecha

Stella S Yu

Bipinchandra N Desai

Stephen Hermann Docter

Hwang-Fun Lu

Stevan Wakefield Djuric

Balekudru Devadas

Peter Gerrard Ruminski

Mark Laurence Boys

Chi-Dean Liang

Srinivasan Raj Nagarajan

Dale P Spangler

Joseph Gerace Rico

Lori A Schretzman

John Jeffrey Talley

Mark G Currie

Michael B Tollefson

Craig N Zimmerman

G Todd Milne

Yi Yu

Brian Cali

Renee Huff

Scott B Mohler

Yueh-Tyng Chien

Yaping Wang

John Adam Wendt

Glen J Gesicki

Richard M Weier

Francis J Koszyk

Kevin Sprott

Xiangdong Xu

Shashidhar N Rao

Ara Mermerian

Timothy Claude Barden

James Philip Pearson

Charles Kim

Jane Yang

Victoria Leigh Downs

Albert Khilevich

Wilmin Bartolini

Heather Stenmark

Regina Lundigran

Hongwei Wu

Hung-Fun Lu

Nagarajan R Srinivasan

Yu Yi

Mihir D Parikh

Stella Siu-tzyy Yu

Jing Jing Yang

Mark A, Russell

Indoles that have activity as inhibitors of FAAH are described as are indoles and indole derivatives that have activity as inhibitors of DAO.

Useful indole compounds

Modulators of the CRTH2 receptor and their use in the treatment of various disorders, including asthma are described.

Modulators of CRTH2 activity

The present invention relates to a class of compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of Formula (I), and methods of selectively antagonizing the &#x3b1;&#x3bd;&#x3b2;and/or the &#x3b1;&#x3bd;&#x3b2;integrin without significantly antagonizing the IIb/IIIa integrin. 

Heteroarylakanoic acids as intergrin receptor antagonists

The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &#x3b1;&#x3b2;and/or the &#x3b1;&#x3b2;integrin without significantly inhibiting the &#x3b1;&#x3b2;integrin.

Thiazole compounds as integrin receptor antagonists derivatives

The present invention relates to a class of compounds represented by the Formula Ior a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &#x3b1;&#x3b2;and/or &#x3b1;&#x3b2;integrin.

Cycloalkyl alkanoic acids as integrin receptor antagonists

The present invention relates to a class of compounds represented by the Formula Ior a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively antagonizing the &#x3b1;&#x3b2;and/or the &#x3b1;&#x3b2;integrin without significantly antagonizing the IIb/IIIa or &#x3b1;&#x3b2;integrin.

Heteroarylalkanoic acids as integrin receptor antagonists

Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives

The present invention relates to a class of compounds represented by the Formula IWherein Ais a pyridinyl of the formulaoptionally substituted by one or more Rselected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl, thioalkyl, haloalkyl, cyano, amino alkylamino, halogen, acylamino, sulfonamide and &#x2014;COR; and R is hydroxy, alkoxy, alkyl or amino; and pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &#x3b1;&#x3b2;and/or &#x3b1;&#x3b2;integrin.

Gem-substituted &agr;v&bgr;3 antagonists

The present invention provides compounds of the formula Ar &mdash;Q&mdash;Ar &mdash;Y&mdash;R&mdash;Z and pharmaceutically acceptable salts thereof wherein Ar and Ar are optionally substituted aryl moieties, Z is an optionally substituted nitrogen-containing moiety which may be an acyclic, cyclic or bicyclic amine or an optionally substituted monocyclic or bicyclic nitrogen-containing heteroaromatic moiety; Q is a linking group capable of linking two aryl groups; R is an alkylene moiety; Y is a linking moiety capable of linking an aryl group to an alkylene moiety and wherein Z is bonded to R through a nitrogen atom. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of inflammatory diseases which are mediated by LTB production, such as psoriasis, ulcerative colitis, IBD and asthma.

LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use

Alkylaminoalkyl-sulfonyl-terminated &bgr;-alanineamide amino-diol compounds for treatment of hypertension

The present invention provides compounds having the structure:

LTA4 hydrolase inhibitors

The present invention relates to a class of compounds represented by Formula I

Para-substituted phenylene derivatives

The present invention provides compounds having the structure

LTA.sub.4, hydrolase inhibitors

Compounds characterized generally as alkylaminoalkyl-terminated .beta.-alanineamide amino diol derivatives are useful as renin inhibitors for the treatment of hypertension. Compounds of particular interest are those of the formula ##STR1## wherein n is two or three; wherein x is a number selected from zero, one and two; wherein R.sup.2 is selected from hydrido, methyl, ethyl and phenyl; wherein R.sup.3 is selected from hydrido, cyclohexylmethyl, benzyl, fluorobenzyl, chlorobenzyl, napthylmethyl, fluoronaphthylmethyl and chloronaphthylmethyl; wherein R.sup.5 is methyl; wherein R.sup.7 is cyclohexylmethyl; wherein R.sup.8 is selected from n-propyl, isobutyl, cyclopropyl, cyclopropylmethyl, allyl and vinyl; and wherein each of R.sup.9 and R.sup.10 is a group independently selected from methyl, ethyl and isopropyl; or a pharmaceutically-acceptable salt thereof.

Alkylaminoalkyl-sulfonyl-terminated .beta.-alanineamide amino-diol

Growing community of inventors

Glenview, IL, United States of America

Barbara B Chen